About Thalia

Thalia’s experienced management team aimsto deliver RNA therapies that improve patient longevity and quality of life while reducing the long-term burden and cost of cancer and cardiovascular disease on healthcare systems worldwide.

miRisten for AML

The Company’s lead asset is a first-in-class microRNA therapeutic, “miRisten”, in Phase 1 clinical development for relapsed or refractory Acute Myeloid Leukemia (AML). miRisten targets miR-126, which is highly expressed in leukemia stem cells, and offers the potential to limit treatment resistance and relapse.

AML is a rare aggressive cancer of white blood cells. Around 22,000 patients annually in the US are diagnosed with AML, and only 1 in 3 patients survives for five years from diagnosis.¹ Older patients face both a higher likelihood of developing AML and substantially worse five-year survival odds than younger patients.

¹ National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program, Cancer Stat Facts: Acute Myeloid Leukemia (AML), available here.

 Bispecific siRNA for lowering cardiovascular risk

Thalia is advancing a novel long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein(a), “Lp(a)”, two genetically driven independent drivers of cardiovascular risk.

Cardiovascular disease remains among the leading causes of global morbidity and mortality. Elevated PCSK9 and Lp(a) levels are strongly associated with increased cardiovascular risk; durable reduction of both these key drivers of disease is expected to significantly reduce cardiovascular events and save lives.

RNA delivery technology

In parallel to this new strategy, Thalia continues to develop its proprietary Nuvec® technology for the delivery of RNA therapeutics.

The Company is listed on the AIM market of the London Stock Exchange and is headquartered in London.